NO330353B1 - Stabilisert farmasoytisk materiale i lyofilisert form - Google Patents
Stabilisert farmasoytisk materiale i lyofilisert form Download PDFInfo
- Publication number
- NO330353B1 NO330353B1 NO20010893A NO20010893A NO330353B1 NO 330353 B1 NO330353 B1 NO 330353B1 NO 20010893 A NO20010893 A NO 20010893A NO 20010893 A NO20010893 A NO 20010893A NO 330353 B1 NO330353 B1 NO 330353B1
- Authority
- NO
- Norway
- Prior art keywords
- material according
- compound
- group
- substituted
- phenyl
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims description 68
- 150000001875 compounds Chemical class 0.000 claims description 87
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 125000004122 cyclic group Chemical group 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000003381 stabilizer Substances 0.000 claims description 26
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 24
- 125000002252 acyl group Chemical group 0.000 claims description 23
- 239000008101 lactose Substances 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 150000002016 disaccharides Chemical class 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 11
- 150000004676 glycans Chemical class 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000600 disaccharide group Chemical group 0.000 claims 1
- -1 heterocyclic carboxylic acids Chemical class 0.000 description 65
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 48
- 125000000623 heterocyclic group Chemical group 0.000 description 20
- 125000003545 alkoxy group Chemical group 0.000 description 18
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 description 14
- 125000001113 thiadiazolyl group Chemical group 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 11
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 10
- 125000004193 piperazinyl group Chemical group 0.000 description 10
- 125000004434 sulfur atom Chemical group 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000006530 (C4-C6) alkyl group Chemical group 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241001149962 Sporothrix Species 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 201000000317 pneumocystosis Diseases 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228193 Aspergillus clavatus Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000203233 Aspergillus versicolor Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 241000033335 Cladophialophora bantiana Species 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 241001527609 Cryptococcus Species 0.000 description 1
- 241000235555 Cunninghamella Species 0.000 description 1
- 241000235556 Cunninghamella elegans Species 0.000 description 1
- 241000223233 Cutaneotrichosporon cutaneum Species 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 241000223682 Exophiala Species 0.000 description 1
- 241000248325 Exophiala dermatitidis Species 0.000 description 1
- 241000308443 Exophiala spinifera Species 0.000 description 1
- 241000122862 Fonsecaea Species 0.000 description 1
- 241000122864 Fonsecaea pedrosoi Species 0.000 description 1
- 208000014260 Fungal keratitis Diseases 0.000 description 1
- 208000004770 Fusariosis Diseases 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- 201000003950 Geotrichosis Diseases 0.000 description 1
- 241000159512 Geotrichum Species 0.000 description 1
- 244000168141 Geotrichum candidum Species 0.000 description 1
- 235000017388 Geotrichum candidum Nutrition 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000487062 Histoplasma capsulatum var. capsulatum Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000144128 Lichtheimia corymbifera Species 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000041810 Mycetoma Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical class CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001537205 Paracoccidioides Species 0.000 description 1
- 206010033767 Paracoccidioides infections Diseases 0.000 description 1
- 201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
- 206010064458 Penicilliosis Diseases 0.000 description 1
- 241000222831 Phialophora <Chaetothyriales> Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 206010035660 Pneumocystis Infections Diseases 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010073756 Pneumocystis jirovecii infection Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000223596 Pseudallescheria Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000293024 Rhizopus microsporus var. rhizopodiformis Species 0.000 description 1
- 240000005384 Rhizopus oryzae Species 0.000 description 1
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000223598 Scedosporium boydii Species 0.000 description 1
- 241000122799 Scopulariopsis Species 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 206010067409 Trichophytosis Diseases 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 241001634961 Trichosporon asahii Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005138 alkoxysulfonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 210000000537 nasal bone Anatomy 0.000 description 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000009838 otomycosis Diseases 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical class C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18771399 | 1999-07-01 | ||
| PCT/JP2000/004381 WO2001002002A1 (en) | 1999-07-01 | 2000-06-29 | Stabilized pharmaceutical composition in lyophilized form |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20010893D0 NO20010893D0 (no) | 2001-02-22 |
| NO20010893L NO20010893L (no) | 2001-04-24 |
| NO330353B1 true NO330353B1 (no) | 2011-04-04 |
Family
ID=16210881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20010893A NO330353B1 (no) | 1999-07-01 | 2001-02-22 | Stabilisert farmasoytisk materiale i lyofilisert form |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6774104B1 (zh) |
| EP (1) | EP1107777B1 (zh) |
| JP (2) | JP3381722B2 (zh) |
| KR (1) | KR100454784B1 (zh) |
| CN (2) | CN100352495C (zh) |
| AR (1) | AR024634A1 (zh) |
| AT (1) | ATE280583T1 (zh) |
| AU (1) | AU752265B2 (zh) |
| BR (2) | BR0006823A (zh) |
| CA (1) | CA2341568C (zh) |
| CZ (1) | CZ295720B6 (zh) |
| DE (1) | DE60015279T2 (zh) |
| ES (1) | ES2225161T3 (zh) |
| HK (2) | HK1040057B (zh) |
| HU (1) | HU229089B1 (zh) |
| ID (1) | ID29468A (zh) |
| IL (2) | IL141455A0 (zh) |
| MX (1) | MXPA01000601A (zh) |
| NO (1) | NO330353B1 (zh) |
| NZ (1) | NZ510290A (zh) |
| OA (1) | OA11601A (zh) |
| PL (1) | PL200141B1 (zh) |
| PT (1) | PT1107777E (zh) |
| RU (1) | RU2251411C2 (zh) |
| TR (1) | TR200100609T1 (zh) |
| TW (1) | TWI233805B (zh) |
| WO (1) | WO2001002002A1 (zh) |
| ZA (1) | ZA200101589B (zh) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| ITMI20021040A1 (it) * | 2002-05-16 | 2003-11-17 | Novuspharma Spa | Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale |
| CN1293880C (zh) * | 2002-07-31 | 2007-01-10 | 千寿制药株式会社 | 水性液体制剂和光稳定的水性液体制剂 |
| US8877168B1 (en) | 2002-07-31 | 2014-11-04 | Senju Pharmaceuticals Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
| US20060074014A1 (en) * | 2002-11-18 | 2006-04-06 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| WO2004045637A1 (en) * | 2002-11-18 | 2004-06-03 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US7119061B2 (en) * | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
| EP1721610B1 (en) | 2004-03-04 | 2009-05-13 | Eisai R&D Management Co., Ltd. | Composition containing benzamidine derivative and method for stabilizing benzamidine derivative |
| WO2005111033A2 (en) * | 2004-05-19 | 2005-11-24 | Neurosearch A/S | Novel azabicyclic aryl derivatives |
| WO2006053383A1 (en) * | 2004-11-22 | 2006-05-26 | Anadis Ltd | Bioactive compositions |
| KR101307999B1 (ko) * | 2004-12-01 | 2013-09-12 | 니폰 조키 세야쿠 가부시키가이샤 | 건조물 및 그 제조방법 |
| CA2614592A1 (en) * | 2005-07-20 | 2007-01-25 | Kyowa Medex Co., Ltd. | Method for stabilization of peptides in a biological sample |
| CN1962852B (zh) * | 2006-11-27 | 2011-11-09 | 西北农林科技大学 | 红景天多糖在制备抗冻剂中的新用途及其产品和制备方法 |
| CN102614492B (zh) * | 2011-01-31 | 2013-12-11 | 上海天伟生物制药有限公司 | 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物 |
| CN102614491B (zh) | 2011-01-31 | 2014-04-16 | 上海天伟生物制药有限公司 | 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途 |
| MX368854B (es) * | 2012-05-22 | 2019-10-18 | Paion Uk Ltd | Composiciones que comprenden benzodiazepinas de acción corta. |
| US20140274991A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| KR102329764B1 (ko) | 2013-03-15 | 2021-11-23 | 머크 샤프 앤드 돔 코포레이션 | 세프톨로잔 항균성 조성물 |
| CN103330932B (zh) * | 2013-04-26 | 2015-12-23 | 江苏豪森药业股份有限公司 | 一种米卡芬净或其盐的药物组合物 |
| CN103330933B (zh) * | 2013-04-26 | 2015-08-05 | 江苏豪森药业股份有限公司 | 含有米卡芬净或其盐的药物组合物 |
| PL3003298T3 (pl) * | 2013-06-05 | 2024-07-15 | The University Of British Columbia | Związki antyfibrogenne, sposoby ich zastosowania |
| EP3043797B1 (en) | 2013-09-09 | 2020-04-08 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
| US20150094293A1 (en) | 2013-09-27 | 2015-04-02 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
| KR101611349B1 (ko) | 2014-04-14 | 2016-04-12 | 신우철 | 안정성이 개선된 밀크씨슬 엑스의 제형 |
| EP3150621A4 (en) * | 2014-05-29 | 2017-12-27 | Shanghai Techwell Biopharmaceutical Co., Ltd | Composition of cyclic peptide compound, preparation method for same, and uses thereof |
| JP6779787B2 (ja) * | 2014-12-05 | 2020-11-04 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | ジアザビシクロオクタン誘導体の結晶及び安定な凍結乾燥製剤の製造法 |
| WO2016107890A1 (en) | 2014-12-31 | 2016-07-07 | Galenicum Health S.L. | Stable pharmaceutical compositions comprising micafungin |
| EP3058958B1 (en) | 2015-02-23 | 2018-09-19 | Selectchemie AG | Anidulafungin composition |
| WO2018112330A1 (en) | 2016-12-16 | 2018-06-21 | Baxter International Inc. | Micafungin compositions |
| US11185527B2 (en) | 2017-06-26 | 2021-11-30 | Wayne State University | Methods and compositions relating to steroid hormone receptor-dependent cancers |
| RU2666148C1 (ru) * | 2017-10-05 | 2018-09-06 | Общество с ограниченной ответственностью "Новые Антибиотики" | Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана |
| EP3485873A1 (en) | 2017-11-17 | 2019-05-22 | Cadila Healthcare Limited | Stable pharmaceutical injectable compositions of micafungin |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03193735A (ja) | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
| JPH03240727A (ja) | 1990-02-15 | 1991-10-28 | Toyo Jozo Co Ltd | ニューモシスチス・カリニ肺炎治療剤 |
| FI912873A (fi) * | 1990-06-18 | 1991-12-19 | Fujisawa Pharmaceutical Co | Ny polypeptidfoerening och foerfarande foer dess framstaellning. |
| JP3193735B2 (ja) | 1991-07-24 | 2001-07-30 | 株式会社リコー | カラー画像形成装置の搬送装置 |
| JPH0651641A (ja) | 1992-07-30 | 1994-02-25 | Olympus Optical Co Ltd | 湿式現像装置 |
| JPH06172204A (ja) * | 1992-12-09 | 1994-06-21 | Asahi Chem Ind Co Ltd | アクレアシン類含有リポソーム製剤およびその製造法 |
| JP3240727B2 (ja) | 1993-02-25 | 2001-12-25 | ソニー株式会社 | 偏平型陰極線管の画像歪補正装置 |
| IL109615A (en) * | 1993-05-17 | 2000-12-06 | Fujisawa Pharmaceutical Co | Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
| RU2165423C2 (ru) | 1994-10-07 | 2001-04-20 | Фудзисава Фармасьютикал Ко., Лтд. | Полипептидное соединение, способ его получения и фармацевтическая композиция |
| GB9512854D0 (en) * | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
| CN1161462C (zh) * | 1996-03-08 | 2004-08-11 | 藤泽药品工业株式会社 | 环脂肽物的脱酰化方法 |
| AR006598A1 (es) * | 1996-04-19 | 1999-09-08 | Merck Sharp & Dohme | "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación" |
| JPH09301997A (ja) | 1996-05-17 | 1997-11-25 | Yamanouchi Pharmaceut Co Ltd | 新規環状ペプチド系化合物 |
| AUPO371596A0 (en) * | 1996-11-19 | 1996-12-12 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| FR2755857B1 (fr) * | 1996-11-19 | 1998-12-24 | Rhone Poulenc Rorer Sa | Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation |
| AUPO381496A0 (en) * | 1996-11-25 | 1996-12-19 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| JPH10279498A (ja) * | 1997-04-07 | 1998-10-20 | Nippon Shinyaku Co Ltd | 慢性関節リウマチ治療剤 |
| JP3544847B2 (ja) * | 1998-01-16 | 2004-07-21 | 三菱電機株式会社 | 光学的情報再生方法および装置 |
| EP1156782B1 (en) * | 1999-03-03 | 2005-05-04 | Eli Lilly And Company | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| JP2002538097A (ja) * | 1999-03-03 | 2002-11-12 | イーライ リリー アンド カンパニー | 薬学的経口ｅｃｂ処方物および組成物の作製方法 |
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
-
2000
- 2000-06-28 TW TW089112754A patent/TWI233805B/zh not_active IP Right Cessation
- 2000-06-29 AT AT00940916T patent/ATE280583T1/de active
- 2000-06-29 AU AU55722/00A patent/AU752265B2/en active Active
- 2000-06-29 NZ NZ510290A patent/NZ510290A/en not_active IP Right Cessation
- 2000-06-29 TR TR2001/00609T patent/TR200100609T1/xx unknown
- 2000-06-29 CN CNB2004100880760A patent/CN100352495C/zh not_active Expired - Lifetime
- 2000-06-29 WO PCT/JP2000/004381 patent/WO2001002002A1/en active IP Right Grant
- 2000-06-29 BR BR0006823-3A patent/BR0006823A/pt not_active IP Right Cessation
- 2000-06-29 HU HU0103740A patent/HU229089B1/hu unknown
- 2000-06-29 MX MXPA01000601A patent/MXPA01000601A/es active IP Right Grant
- 2000-06-29 OA OA1200100048A patent/OA11601A/en unknown
- 2000-06-29 BR BRPI0006823A patent/BRPI0006823B8/pt unknown
- 2000-06-29 DE DE60015279T patent/DE60015279T2/de not_active Expired - Lifetime
- 2000-06-29 US US09/786,125 patent/US6774104B1/en not_active Expired - Lifetime
- 2000-06-29 IL IL14145500A patent/IL141455A0/xx active IP Right Grant
- 2000-06-29 JP JP2001507492A patent/JP3381722B2/ja not_active Expired - Lifetime
- 2000-06-29 PL PL346297A patent/PL200141B1/pl unknown
- 2000-06-29 CZ CZ20011186A patent/CZ295720B6/cs not_active IP Right Cessation
- 2000-06-29 CN CNB008012164A patent/CN1179748C/zh not_active Expired - Lifetime
- 2000-06-29 RU RU2001108569/15A patent/RU2251411C2/ru active
- 2000-06-29 KR KR10-2001-7002318A patent/KR100454784B1/ko active IP Right Grant
- 2000-06-29 ES ES00940916T patent/ES2225161T3/es not_active Expired - Lifetime
- 2000-06-29 PT PT00940916T patent/PT1107777E/pt unknown
- 2000-06-29 ID IDW20010749A patent/ID29468A/id unknown
- 2000-06-29 EP EP00940916A patent/EP1107777B1/en not_active Expired - Lifetime
- 2000-06-29 CA CA2341568A patent/CA2341568C/en not_active Expired - Lifetime
- 2000-06-30 AR ARP000103372A patent/AR024634A1/es not_active Application Discontinuation
-
2001
- 2001-02-15 IL IL141455A patent/IL141455A/en not_active IP Right Cessation
- 2001-02-22 NO NO20010893A patent/NO330353B1/no not_active IP Right Cessation
- 2001-02-26 ZA ZA200101589A patent/ZA200101589B/en unknown
- 2001-10-10 JP JP2001312701A patent/JP4691866B2/ja not_active Expired - Lifetime
-
2002
- 2002-03-05 HK HK02101689.2A patent/HK1040057B/zh not_active IP Right Cessation
-
2004
- 2004-02-06 US US10/772,281 patent/US7112565B2/en not_active Expired - Lifetime
-
2006
- 2006-01-13 HK HK06100611A patent/HK1080724A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO330353B1 (no) | Stabilisert farmasoytisk materiale i lyofilisert form | |
| US7375081B2 (en) | Therapeutic combination of a pneumocandin derivative and an antifungal agent | |
| CA2774094A1 (en) | Formulations of daptomycin | |
| US8431539B2 (en) | Formulations of daptomycin | |
| AU2011304408B2 (en) | Caspofungin composition | |
| EP1502589B1 (en) | Veterinary aqueous injectable suspensions containing florfenicol | |
| JP5723031B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物 | |
| US20040023858A1 (en) | Antifungal combination therapy | |
| US20030220237A1 (en) | Pharmaceutical composition | |
| WO2002053584A1 (en) | Stabilized pharmaceutical composition in lyophilized form | |
| JP2019135214A (ja) | 溶解時の消泡性に優れかつ安定な凍結乾燥組成物 | |
| US20050004014A1 (en) | New compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0 |
|
| MK1K | Patent expired |